The U.S. FDA has approved Jardiance 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease at risk of progression, Boehringer Ingelheim and Eli Lilly and Company announced.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks
- Scinai Immunotherapeutics announces results from preclinical NanoAbs study
- Eli Lilly initiated with a Buy at DBS Bank
- Novo Nordisk reaches pact with New York AG over insulin prices
